ClinicalTrials.gg
RecruitingNCT07231484Updated Jul 31, 2026

Effects of Grape Consumption on the Immune-Gut Axis in Obesity

An interventional study of Freeze-dried grape powder and Placebo powder in Obesity &Amp; Overweight, sponsored by University of Missouri-Columbia. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by University of Missouri-Columbia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Obesity by University of Missouri-Columbia — 8 open to participants now, 9 under way, none of them phase 3. Obesity · University of Missouri-Columbia.

Planned enrollment
13th of 29
50 · median 40
Started
2025
with 3 others
No phase
21 of 34
1 open now
Registered
31st of 34
by date

Among the 34 studies in Obesity by University of Missouri-Columbia, this one is the 13th largest by planned enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2025, is one of 21 with no phase, and was the 31st registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 34 studies in Obesity by University of Missouri-Columbia are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Obesity by University of Missouri-Columbia, or all of them as a file.
02

Study summary

This study is investigating the benefits of whole freeze-dried grape powder consumption on the immune-gut axis in adults with obesity.

Read the detailed description

The study is a 12-wk randomized, controlled, crossover trial. Participants will be randomized to one of two intervention sequences, either consuming 48g/day of whole freeze-dried grape powder followed by an isocaloric placebo powder or consuming the placebo powder followed by the whole freeze-dried grape powder. Active intervention phases will be 4 weeks in duration followed by a 4-week washout period between treatments.

03

Conditions studied

  • Obesity &Amp; Overweight

Keywords

  • Obesity
  • Immunity
  • Microbiome
  • Gut
  • Grape
  • Stress
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18-60 years
  • Obesity with of 30-45 kg/m2
  • Willingness to consume study foods
  • Consistent diet and activity patterns for 4 weeks
  • Weight stable (\<5kg change over last 3 months)
  • Non-smoker > 1 year or more
  • Not currently consuming an extremely healthy diet

Exclusion criteria

Exclusion Criteria:

  • Study food allergies
  • Regular consumption of grapes or grape-derived products
  • Gastrointestinal disease and/or bariatric surgery
  • Uncontrolled hypertension and blood pressure >180/110
  • Diabetes
  • Illicit drug use
  • History of alcohol or drug abuse
  • Recent use of medications that affect immune function (e.g., )
  • Recent consumption of antibiotics, prebiotics, probiotics, symbiotics, or dietary supplements containing fiber or phytochemicals
  • Pregnant or lactating individuals
  • positivity
  • Recent start of medications that affect metabolism or appetite
  • Drug therapy for coronary artery disease, peripheral artery disease, congestive
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Sequence 1: Grape then Placebo

    Whole freeze-dried grape powder for 4 weeks, 4-week washout, then isocaloric placebo powder for 4 weeks.

    Other: Freeze-dried grape powder · Other: Placebo powder

  • Experimental
    Sequence 2: Placebo then Grape

    Isocaloric placebo powder for 4 weeks, 4-week washout, then whole freeze-dried grape powder for 4 weeks.

    Other: Freeze-dried grape powder · Other: Placebo powder

Interventions

  • OtherFreeze-dried grape powder

    48 g/day oral consumption during the 4-week active period.

  • OtherPlacebo powder

    Isocaloric placebo matched to grape powder; oral consumption during the 4-week active period.

06

What researchers measure

Primary outcomes

  1. Gut microbial diversity

    Assessed via 16s rRNA sequencing

    Time frame: Baseline, Week 4, Week 8, Week 12

  2. LPS-binding protein concentration

    Intestinal permeability marker

    Time frame: Baseline, Week 4, Week 8, Week 12

  3. Cytokine concentrations following PBMC stimulation

    IL-6, IL-10

    Time frame: Baseline, Week 4, Week 12

  4. Perceived stress score

    Assessed using validated Cohen's Perceived Stress Scale. Scores range from 0-56 with higher scores indicating greater stress perceptions.

    Time frame: Baseline, Week 4, Week 8, Week 12

Secondary outcomes

  1. Gut microbiome abundance

    Assessed via 16s rRNA sequencing

    Time frame: Baseline, Week 4, Week 8, Week 12

  2. Inflammatory Markers

    IL-6, IL-10, TNF-alpha, IFN-gamma

    Time frame: Baseline, Week 4, Week 8, Week 12

  3. Body mass

    Measured in kg

    Time frame: Baseline, Week 4, Week 8, Week 12

  4. Body composition

    Fat mass and fat-free mass

    Time frame: Baseline, Week 4, Week 8, Week 12

  5. Anthropometrics

    Waist circumference, hip circumference, thigh circumference

    Time frame: Baseline, Week 4, Week 8, Week 12

  6. Glucoregulation

    Fasting glucose concentrations

    Time frame: Baseline, Week 4, Week 8, Week 12

  7. Insulinemic biomarker concentrations

    Insulin concentrations

    Time frame: Baseline, Week 4, Week 8, Week 12

  8. Lipid profile

    LDL, HDL, triglycerides, total cholesterol

    Time frame: Baseline, Week 4, Week 8, Week 12

  9. Blood pressure

    Diastolic and systolic blood pressure

    Time frame: Baseline, Week 4, Week 8, Week 12

  10. Dietary intake using 24-hour recalls

    24-hour diet recall using Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA-24).

    Time frame: Every week

  11. Physical activity

    Activity assessment using Actigraphs

    Time frame: Baseline, Week 4, Week 8, Week 12

  12. Sleep indices from Actigraphs

    Assessed using Actigraphs

    Time frame: Baseline, Week 4, Week 8, Week 12

  13. 24-hour appetite ratings

    24-hour appetite ratings assessed using Visual Analog Scale. For each question scores range from 0-100 with higher scores indicating "extremely" and lower scores indicating "not at all."

    Time frame: Baseline, Week 4, Week 8, Week 12

  14. Palatability rating of foods

    Hedonic general labelled magnitude scale (gLMS). Scores range from 0 to 100.

    Time frame: Every week

  15. Acceptance rating of foods

    9-point food action rating scale (1-9) with higher scores indicating a higher food rating.

    Time frame: Every week

  16. Dietary Intake over past month

    Assessed using Food Frequency Questionnaires

    Time frame: Baseline, Week 4, Week 8, Week 12

  17. IPAQ Score

    Measured using the International Physical Activity Questionnaire (IPAQ). Activity levels categorized as high, moderate, or low based on IPAQ scoring procedure.

    Time frame: Baseline, Week 4, Week 8, Week 12

  18. Sleep indices from sleep diary

    Assessed using sleep diary

    Time frame: Baseline, Week 4, Week 8, Week 12

Other outcomes

  1. Memory indices

    Assessed using memory tests

    Time frame: Baseline, Week 4, Week 8, Week 12

  2. Attention indices

    Assessed using d2 test of attention

    Time frame: Baseline, Week 4, Week 8, Week 12

07

Study locations

1 of 1 sites recruiting
  • University of Missouri-Columbia
    Columbia, Missouri 65211, United States
    Recruiting
    • Caitlyn Winn, MS · Contactcawq6x@umsystem.edu · 2072108049
    • Jaapna Dhillon, PhD · Principal investigator
    • Caitlyn Winn, MS · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported here after deidentification (ie; text, tables, figures, and appendices)

Supporting information: Study protocol

Time frame: Immediately following publication. No end date.

Access criteria: Data will be deposited in online repositories

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2027, 24 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 24 months is close to that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2025
First posted
Nov 17, 2025
StartActual
Dec 19, 2025
Primary completionEst.
Dec 20, 2027
CompletionEst.
Dec 30, 2027
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07231484
Collaborators
California Table Grape Commission
Responsible party
Jaapna Dhillon (Assistant Professor, University of Missouri-Columbia) — Principal investigator
First posted
Nov 17, 2025
Start date
Dec 19, 2025
Primary completion
Dec 20, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Jul 31, 2026

Study contacts

Jaapna Dhillon PhD, PhD
Contact
jdhillon@health.missouri.edu
573-884-2103
Caitlyn Winn, MS
Contact
cawq6x@umsystem.edu
207-210-8049

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion